Spinreact Includes AbD Serotec Antibodies in Clinical Diagnostic Kits

The diagnostic and research antibody segment of MorphoSys (Munich, Germany), AbD Serotec, and Spinreact S.A. (Girona, Spain) have signed a supply agreement, which initially covers the use of two antibodies for a series of clinical diagnostic kits. AbD Serotec will continuously supply Spinreact with antibody material. Financial details of the agreement were not disclosed.

MorphoSys is a biotechnology company focused on the generation of fully human antibodies as a means to discover and develop antibody-based drugs against life-threatening diseases. MorphoSys aims to establish human combinatorial antibody library (HuCAL) as the technology of choice for antibody generation in diagnostics. The HuCAL libraries comprise highly diverse, fully human synthetic antibodies that are highly given to engineering through their modular CDR design.

Spinreact, S.A. is a Concateno group company and deals in latex reagents and hemostasis. It is developing a project with new latex particles and human antibodies. The company manufactures in vitro diagnostic (IVD) reagents and produces reagents for biochemistry, serology, and immunochemistry.

"Today's news represents another example of the higher value-added projects that AbD Serotec is increasingly pursuing in line with our strategy to increase our efforts on the diagnostics side of the business," commented Dieter Feger, senior vice president and head of MorphoSys's AbD Serotec unit. "We welcome the decision of Spinreact to use AbD Serotec antibodies in its clinical diagnostic reagents."

Related Links:
MorphoSys
Spinreact S.A.